Education
About Us
Working with TipRanks
Follow Us
Charles River Laboratories Intl (CRL)
NYSE:CRL
Earnings Data
Report Date
Jul 30, 2025TBA Not Confirmed
Period Ending
2025 (Q2)Consensus EPS Forecast
2.5Last Year’s EPS
2.8Same Quarter Last Year
Based on 15 Analysts Ratings
Earnings Call Summary
Earnings Call Date:May 07, 2025
|% Change Since: 17.49%
|Next Earnings Date:Jul 30, 2025
Earnings Call Sentiment|Neutral
The earnings call reflected a cautious yet optimistic outlook, with strong cost management and improved DSA performance offsetting revenue declines across segments. While there are concerns about NIH funding and challenges in the Manufacturing segment, the company is optimistic about strategic investments and increased guidance.Company Guidance
During the Charles River Laboratories First Quarter 2025 Earnings Conference Call, the company provided an updated financial guidance for the year. They raised their 2025 revenue guidance by 100 basis points to a 2.5% to 4.5% organic decrease and increased their non-GAAP earnings per share guidance by $0.20 at the midpoint, setting a new range of $9.30 to $9.80. This adjustment was primarily driven by better-than-expected DSA performance, where the net book-to-bill ratio returned to above 1x for the first time in over two years, indicating improved quarterly bookings. Despite a 2.7% decrease in revenue to $984.2 million for the first quarter, the operating margin improved to 19.1%, up 60 basis points year-over-year, supported by cost-saving initiatives and favorable mix. Additionally, the company generated approximately $112.4 million in free cash flow and repurchased $350 million in shares during the quarter.Improved DSA Segment Performance
DSA net book-to-bill improved to 1.04x in the first quarter, the first time above 1x in over 2 years, due to improved bookings and a decline in study cancellations.
Strong Cost Savings and Margin Improvement
Operating margin increased by 60 basis points to 19.1% year-over-year, driven by cost savings from restructuring initiatives, contributing to EPS growth of 3.1%.
Increased Financial Guidance
Due to better-than-expected DSA performance, revenue guidance was raised by 100 basis points to a 2.5% to 4.5% decrease organically, and non-GAAP EPS guidance was increased by $0.20 at midpoint.
Growth in Small and Midsized Biotech Revenue
Revenue for small and midsized biotech clients grew for the second consecutive quarter, indicating resilience despite funding challenges.
Successful Strategic Investments
Continued expansion into NAMs with $200 million annual revenue from NAMs-related services, highlighting Charles River's investment in advanced in vitro toxicology, predictive immunotoxicology assays, and organ-on-a-chip platforms.
CRL Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
CRL Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
May 07, 2025 | $115.41 | $136.97 | +18.68% |
Feb 19, 2025 | $154.39 | $165.00 | +6.87% |
Nov 06, 2024 | $188.68 | $214.20 | +13.53% |
Aug 07, 2024 | $228.80 | $199.96 | -12.60% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Charles River Laboratories Intl (CRL) report earnings?
Charles River Laboratories Intl (CRL) is schdueled to report earning on Jul 30, 2025, TBA Not Confirmed.
What is Charles River Laboratories Intl (CRL) earnings time?
Charles River Laboratories Intl (CRL) earnings time is at Jul 30, 2025, TBA Not Confirmed.
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is CRL EPS forecast?
CRL EPS forecast for the fiscal quarter 2025 (Q2) is 2.5.
